Calamos Advisors
ADMA icon

Calamos Advisors’s ADMA Biologics ADMA Stock Holding History

Calamos Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-292,426
Closed -$5.33M – 1197
2025
Q4 		$5.33M Buy
292,426
+159,501
+120% +$2.69M 0.02% 517
2025
Q3 		$1.95M Sell
132,925
-404,395
-75% -$6.93M 0.01% 633
2025
Q2 		$9.78M Buy
537,320
+3,483
+0.7% +$71K 0.04% 411
2025
Q1 		$10.6M Buy
533,837
+107,931
+25% +$1.87M 0.05% 379
2024
Q4 		$7.3M Buy
425,906
+28,154
+7% +$530K 0.03% 459
2024
Q3 		$7.95M Sell
397,752
-205,251
-34% -$3.19M 0.03% 461
2024
Q2 		$6.74M Buy
603,003
+46,405
+8% +$389K 0.03% 476
2024
Q1 		$3.67M Buy
556,598
+306,413
+122% +$1.67M 0.02% 531
2023
Q4 		$1.13M Buy
250,185
+137,749
+123% +$510K 0.01% 657
2023
Q3 		$403K Buy
112,436
+55,212
+96% +$213K ﹤0.01% 724
2023
Q2 		$211K Buy
+57,224
New +$212K ﹤0.01% 784

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Calamos Advisors's ADMA Position: Q1 2026 in Review

Calamos Advisors sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 292,426 shares — an estimated $5.33M sold.

Calamos Advisors first reported a position in ADMA in Q2 2023 and held it in 11 quarters. The position peaked at $10.6M in Q1 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Calamos Advisors reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Calamos Advisors sold 292,426 ADMA Biologics shares in Q1 2026, an estimated $5.33M.
  • Calamos Advisors first reported a position in ADMA Biologics in Q2 2023 and held it in 11 quarters.
  • Calamos Advisors's ADMA Biologics position peaked at $10.6M in Q1 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.